Literature DB >> 16984254

Antitumour effects of temozolomide in a man with a large, invasive prolactin-producing pituitary neoplasm.

Luis V Syro, Humberto Uribe, Luis C Penagos, Leon D Ortiz, Camilo E Fadul, Eva Horvath, Kalman Kovacs.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16984254     DOI： 10.1111/j.1365-2265.2006.02653.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN： 0300-0664            Impact factor:   3.478


× No keyword cloud information.
  26 in total

Review 1.  Temozolomide responsiveness in aggressive corticotroph tumours: a case report and review of the literature.

Authors:  A K Annamalai; A F Dean; N Kandasamy; K Kovacs; H Burton; D J Halsall; A S Shaw; N M Antoun; H K Cheow; R W Kirollos; J D Pickard; H L Simpson; S J Jefferies; N G Burnet; M Gurnell
Journal:  Pituitary       Date:  2012-09       Impact factor: 4.107

2.  Mid-term prognosis of non-functioning pituitary adenomas with high proliferative potential: really an aggressive variant?

Authors:  Yoshikazu Ogawa; Hidefumi Jokura; Kuniyasu Niizuma; Teiji Tominaga
Journal:  J Neurooncol       Date:  2018-01-09       Impact factor: 4.130

3.  Temozolomide for corticotroph pituitary adenomas refractory to standard therapy.

Authors:  Troy H Dillard; S Humayun Gultekin; Johnny B Delashaw; Chris G Yedinak; Edward A Neuwelt; Maria Fleseriu
Journal:  Pituitary       Date:  2011-03       Impact factor: 4.107

4.  MGMT immunoexpression in silent subtype 3 pituitary adenomas: possible therapeutic implications.

Authors:  Michael E Fealey; Bernd W Scheithauer; Eva Horvath; Dana Erickson; Kalman Kovacs; Roger McLendon; Ricardo V Lloyd
Journal:  Endocr Pathol       Date:  2010-09       Impact factor: 3.943

Review 5.  Pituitary carcinoma with intraspinal metastasis: report of two cases and review of the literature.

Authors:  Yin Qian Wang; Tao Fan; Xin Gang Zhao; Cong Liang; Xue Ling Qi; Jian Yi Li
Journal:  Int J Clin Exp Pathol       Date:  2015-08-01

Review 6.  Molecular status of pituitary carcinoma and atypical adenoma that contributes the effectiveness of temozolomide.

Authors:  Akira Matsuno; Mineko Murakami; Katsumi Hoya; Shoko M Yamada; Shinya Miyamoto; So Yamada; Jae-Hyun Son; Hajime Nishido; Fuyuaki Ide; Hiroshi Nagashima; Mutsumi Sugaya; Toshio Hirohata; Akiko Mizutani; Hiroko Okinaga; Yudo Ishii; Shigeyuki Tahara; Akira Teramoto; R Yoshiyuki Osamura
Journal:  Med Mol Morphol       Date:  2013-08-17       Impact factor: 2.309

7.  MGMT promoter methylation and immunoexpression in aggressive pituitary adenomas and carcinomas.

Authors:  Fateme Salehi; Bernd W Scheithauer; Johann M Kros; Queenie Lau; Michael Fealey; Dana Erickson; Kalman Kovacs; Eva Horvath; Ricardo V Lloyd
Journal:  J Neurooncol       Date:  2011-02-11       Impact factor: 4.130

8.  Failure of temozolomide and conventional doses of pegvisomant to attain biochemical control in a severe case of acromegaly.

Authors:  Emilie Morin; France Berthelet; John Weisnagel; Martin Bidlingmaier; Omar Serri
Journal:  Pituitary       Date:  2012-03       Impact factor: 4.107

Review 9.  Management of aggressive pituitary adenomas and pituitary carcinomas.

Authors:  Anthony Heaney
Journal:  J Neurooncol       Date:  2014-03-02       Impact factor: 4.130

Review 10.  MGMT immunoexpression in aggressive pituitary adenoma and carcinoma.

Authors:  Queenie Lau; Bernd Scheithauer; Kalman Kovacs; Eva Horvath; Luis V Syro; Ricardo Lloyd
Journal:  Pituitary       Date:  2010-12       Impact factor: 4.107
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.